tci Medicare Compliance & Reimbursement - 2005 Issue 4
Drug Coverage: Plans And PBMs Cheer, Big Pharma Jeers Guidelines
Subscribe or sign in to view the full article.
Article Overview
This article covers the final United States Pharmacopeia guidance for Medicare Part D drug categories, classes, and related key drug types, along with how CMS and industry stakeholders responded. It is relevant to Medicare formulary stakeholders, health plans, pharmacy benefit managers, pharmaceutical manufacturers, and coding or compliance professionals tracking Part D coverage policy. The discussion focuses on the structure of the classification framework, the role of the safe harbor, and the policy debate around how the guidance may be interpreted and applied.
Why This Topic Matters
The article helps readers understand a Medicare Part D coverage policy change that affects formulary construction, compliance expectations, and how plans may be evaluated by CMS. It also highlights competing viewpoints from insurers, PBMs, and manufacturers, which may influence how the guidance is used and challenged.
What You Will Learn
- How USP’s final Medicare Part D drug-classification guidance is framed
- How the CMS safe-harbor concept relates to formulary classifications
- Why insurers, PBMs, and manufacturers viewed the guidance differently
- How key drug types are positioned relative to drug classes
- What policy questions remain around Medicare formulary adequacy and interpretation
Who Should Read This
- Medicare Part D plan administrators
- Pharmacy benefit managers
- Health plan compliance staff
- Pharmaceutical manufacturers
- Healthcare policy analysts
- Medical coding and reimbursement professionals
Subscribe or sign in to view the full article.
Thank you for choosing Find-A-Code, please Sign In to remove ads.
Quick, Current, Complete - www.findacode.com